{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:13:13Z","timestamp":1794665593216,"version":"4.9.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Describe real-world use, adherence, persistence, and risk of non-fatal cardiovascular events (CVE) and mortality among patients receiving four-drug antihypertensive therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This was a retrospective, longitudinal cohort study of Italian administrative healthcare databases (n = 7 160 298). Eligible patients were \u226518 years and received four-drug therapy between 2018 and 2022. Class- and molecule-level subcohort analyses required data for \u22651 year either side of four-drug therapy identification. Adherence and persistence were based on prescription availability. A Cox proportional hazards model was used for risk assessment.<\/jats:p>\n                    <jats:p>Among 228 594 eligible patients, 113 755 received either an angiotensin-converting enzyme inhibitor (ACEi; n = 57 473) or angiotensin II receptor blocker (n = 56 282), thiazide\/thiazide-like diuretic (DIU), calcium channel blocker (CCB), and a fourth class (mostly beta-blockers [BBs]; n = 87 022).<\/jats:p>\n                    <jats:p>In the class subcohort (ACEi + DIU + CCB + BB; n = 41 903), high adherence was more frequent among patients receiving two (52.1%) vs. three (40.2%) or four (25.0%) pills (global P &amp;lt; 0.001); persistence was also improved (P &amp;lt; 0.02 from 6 months). Adherence and persistence were significantly higher with two vs. three pills in the molecule subcohort (perindopril, indapamide, amlodipine, and bisoprolol; n = 8007). For persistent vs. non-persistent patients, there was a risk reduction for CVE (12.4%; P &amp;lt; 0.001) and mortality (16.4%; P &amp;lt; 0.001) in the class subcohort, with similar findings in the molecule subcohort (20.9% [P = 0.003] and 20.9% [P = 0.002], respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients receiving four-drug antihypertensive therapy, adherence and persistence were significantly improved with lower pill burden. Persistence was associated with lower risks of CVE and mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag073","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:53:33Z","timestamp":1789127613000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-world analysis of adherence, persistence, and outcomes in patients receiving four-drug antihypertensive therapy"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-3176","authenticated-orcid":false,"given":"Giuseppe","family":"Mancia","sequence":"first","affiliation":[{"name":"Universit\u00e0 Milano-Bicocca , Piazza dell\u2019Ateneo Nuovo, 1, 20126 Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Brouwers","sequence":"additional","affiliation":[{"name":"AZORG Clinic Aalst, Cardiovascular Center Aalst , 9300 Aalst ,","place":["Belgium"]},{"name":"Department of Experimental Pharmacology, Vrije Universiteit Brussel , 1050 Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Calabria","sequence":"additional","affiliation":[{"name":"Health, Economics & Outcomes Research, CliCon S.r.l. Societ\u00e0 Benefit , 40137 Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Leogrande","sequence":"additional","affiliation":[{"name":"Health, Economics & Outcomes Research, CliCon S.r.l. Societ\u00e0 Benefit , 40137 Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-6659","authenticated-orcid":false,"given":"Luca","family":"Degli Esposti","sequence":"additional","affiliation":[{"name":"Health, Economics & Outcomes Research, CliCon S.r.l. Societ\u00e0 Benefit , 40137 Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"Desideri","sequence":"additional","affiliation":[{"name":"Department of Medical and Cardiovascular Sciences, Sapienza University of Rome , 00185 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Narkiewicz","sequence":"additional","affiliation":[{"name":"Department of Hypertension and Diabetology, Medical University of Gda\u0144sk , 80-210 Gda\u0144sk ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"2026092512412997700_pvag073-B1","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2026092512412997700_pvag073-B2","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026092512412997700_pvag073-B3","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"2026092512412997700_pvag073-B4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11906-022-01173-w","article-title":"The burden of resistant hypertension across the world","volume":"24","author":"Brant","year":"2022","journal-title":"Curr Hypertens Rep"},{"key":"2026092512412997700_pvag073-B5","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.125.25659","article-title":"Contemporary prevalence and treatment patterns among US adults with apparent treatment-resistant hypertension","volume":"83","author":"Earle","year":"2026","journal-title":"Hypertension"},{"key":"2026092512412997700_pvag073-B6","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/HYPERTENSIONAHA.123.20894","article-title":"Characterization of individuals with apparent resistant hypertension using contemporary guidelines: insights from CV-QUIC","volume":"80","author":"Ebinger","year":"2023","journal-title":"Hypertension"},{"key":"2026092512412997700_pvag073-B7","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s12325-023-02451-y","article-title":"Adherence to triple single-pill combination of perindopril\/indapamide\/amlodipine: findings from real-world analysis in Italy","volume":"40","author":"Borghi","year":"2023","journal-title":"Adv Ther"},{"key":"2026092512412997700_pvag073-B8","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/HJH.0000000000003497","article-title":"Adherence and related cardiovascular outcomes to single pill vs. separate pill administration of antihypertensive triple-combination therapy","volume":"41","author":"Rea","year":"2023","journal-title":"J Hypertens"},{"key":"2026092512412997700_pvag073-B9","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","article-title":"Adherence to single-pill versus free-equivalent combination therapy in hypertension","volume":"77","author":"Parati","year":"2021","journal-title":"Hypertension"},{"key":"2026092512412997700_pvag073-B10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYP.0000000000000203","article-title":"Medication adherence and blood pressure control: a scientific statement from the American Heart Association","volume":"79","author":"Choudhry","year":"2022","journal-title":"Hypertension"},{"key":"2026092512412997700_pvag073-B11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/HJH.0b013e328342ca97","article-title":"Better compliance to antihypertensive medications reduces cardiovascular risk","volume":"29","author":"Corrao","year":"2011","journal-title":"J Hypertens"},{"key":"2026092512412997700_pvag073-B12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/eurheartj\/ehaf744","article-title":"Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study","volume":"47","author":"Rea","year":"2026","journal-title":"Eur Heart J"},{"key":"2026092512412997700_pvag073-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2024.05.033","article-title":"2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension","volume":"126","author":"Kreutz","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026092512412997700_pvag073-B14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/HJH.0000000000003368","article-title":"Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials","volume":"41","author":"Chalmers","year":"2023","journal-title":"J Hypertens"},{"key":"2026092512412997700_pvag073-B15","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/HJH.0b013e328342c845","article-title":"Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)","volume":"29","author":"Collier","year":"2011","journal-title":"J Hypertens"},{"key":"2026092512412997700_pvag073-B16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","journal-title":"Lancet"},{"key":"2026092512412997700_pvag073-B17","doi-asserted-by":"crossref","first-page":"e00258","DOI":"10.1161\/HYP.0000000000000258","article-title":"Single-pill combination therapy for the management of hypertension: a scientific statement from the American Heart Association","volume":"83","author":"King","year":"2026","journal-title":"Hypertension"},{"key":"2026092512412997700_pvag073-B18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40292-026-00784-7","article-title":"Hypertension treatment with angiotensin receptor blockers and other antihypertensive agents: a real-world registry from a high-volume specialized center over twodecades","volume":"33","author":"Tocci","year":"2026","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"2026092512412997700_pvag073-B19","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2026092512412997700_pvag073-B20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41440-025-02432-4","article-title":"Doxazosin GITS (gastrointestinal therapeutic system) is an actor to consider in the control of hypertension. A narrative review","volume":"49","author":"Camafort","year":"2026","journal-title":"Hypertens Res"},{"key":"2026092512412997700_pvag073-B21","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S0140-6736(16)30076-9","article-title":"PATHWAY-2: spironolactone for resistant hypertension","volume":"387","author":"Gkaliagkousi","year":"2016","journal-title":"Lancet"},{"key":"2026092512412997700_pvag073-B22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(16)30075-7","article-title":"PATHWAY-2: spironolactone for resistant hypertension","volume":"387","author":"Boutari","year":"2016","journal-title":"Lancet"},{"key":"2026092512412997700_pvag073-B23","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/HJH.0000000000002398","article-title":"Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals","volume":"38","author":"Lawson","year":"2020","journal-title":"J Hypertens"},{"key":"2026092512412997700_pvag073-B24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/14737167.2023.2293199","article-title":"Impact of single-pill combinations versus free-equivalent combinations on adherence and persistence in patients with hypertension and dyslipidemia: a systematic literature review and meta-analysis","volume":"24","author":"Kengne","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2026092512412997700_pvag073-B25","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/HJH.0000000000004111","article-title":"Patterns of prescription of antihypertensive medications in Poland: a one-year assessment of initiation and persistence of therapy in a nationwide population cohort","volume":"43","author":"Prejbisz","year":"2025","journal-title":"J Hypertens"},{"key":"2026092512412997700_pvag073-B26","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/ajh\/hpab083","article-title":"Adherence to treatment by initial antihypertensive mono and combination therapies","volume":"34","author":"Rea","year":"2021","journal-title":"Am J Hypertens"},{"key":"2026092512412997700_pvag073-B27","doi-asserted-by":"publisher","first-page":"ehag022","DOI":"10.1093\/eurheartj\/ehag022","article-title":"Quadruple vs triple therapy for resistant hypertension: the QUADRO trial","author":"Taddei","year":"2026","journal-title":"Eur Heart J"},{"key":"2026092512412997700_pvag073-B28","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1161\/HYPERTENSIONAHA.122.20810","article-title":"Improved persistence to medication, decreased cardiovascular events and reduced all-cause mortality in hypertensive patients with use of single-pill combinations: results from the START-study","volume":"80","author":"Schmieder","year":"2023","journal-title":"Hypertension"},{"key":"2026092512412997700_pvag073-B29","author":"World Health Organization"},{"key":"2026092512412997700_pvag073-B30"},{"key":"2026092512412997700_pvag073-B31","doi-asserted-by":"crossref","first-page":"e5641","DOI":"10.1097\/MD.0000000000005641","article-title":"Nonadherence to antihypertensive drugs: a systematic review and meta-analysis","volume":"96","author":"Abegaz","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2026092512412997700_pvag073-B32","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/eurheartj\/ehz149","article-title":"Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk","volume":"40","author":"B\u00f6hm","year":"2019","journal-title":"Eur Heart J"},{"key":"2026092512412997700_pvag073-B33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/HJH.0000000000002222","article-title":"Women discontinue antihypertensive drug therapy more than men. Evidence from an Italian population-based study","volume":"38","author":"Rea","year":"2020","journal-title":"J Hypertens"},{"key":"2026092512412997700_pvag073-B34","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","article-title":"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial","volume":"398","author":"Chow","year":"2021","journal-title":"Lancet"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag073\/71079613\/pvag073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag073\/71079613\/pvag073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:41:41Z","timestamp":1790354501000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article\/doi\/10.1093\/ehjcvp\/pvag073\/8794528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag073","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"pvag073"}}